Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 12:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Gadolinium-based contrast Clear all
Completed No phase listed Observational

Immunoscore in Rectal Cancer

NCT02017509
View directory record Official record
Conditions
Cancer of the Rectum, Neoplasms, Rectal, Rectal Cancer, Rectal Tumors, Rectal Adenocarcinoma
Interventions
Diagnostic Biopsy and Surgical Procedure, Intravoxel incoherent motion MRI (IVIM), Dynamic Contrast Enhanced MRI (DCE-MRI), RNA gene expression analysis
Procedure · Genetic
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 25, 2026, 12:20 AM EDT
Recruiting Early Phase 1 Interventional

Virtual Histology of the Bladder Wall for Bladder Cancer Staging

NCT04369560
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
Magnetic Resonance Imaging, Gadobutrol intravesical administration (4mM), Ferumoxytol intravesical administration (5 mM)
Diagnostic Test · Drug
Lead sponsor
Jodi Maranchie
Other
Eligibility
18 Years to 90 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 25, 2026, 12:20 AM EDT
Terminated Early Phase 1 Interventional

3T MRI Biomarkers of Glioma Treatment Response

NCT01996527
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
3-Tesla magnetic resonance imaging, CEST-MRI, DW-MRI, DCE-MRI, DSC-MRI, IV administration of gadolinium-containing contrast agent
Device · Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 16, 2017 · Synced Sep 25, 2026, 12:20 AM EDT
Completed No phase listed Observational Results available

Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist

NCT00744939
View directory record Official record
Conditions
Fibrosis, Kidney Failure, Renal Insufficiency
Interventions
Gadopentetate dimeglumine (Magnevist, BAY86-4882)
Drug
Lead sponsor
Bayer
Industry
Eligibility
2 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
26
States / cities
Phoenix, Arizona • Chula Vista, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2014 · Synced Sep 25, 2026, 12:20 AM EDT
Recruiting No phase listed Observational

Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis

NCT06265272
View directory record Official record
Conditions
Liver Cirrhosis, Hepatic Cell Carcinoma, Portal Hypertension
Interventions
Injection of a gadolinium contrast agen, Radiotracer Injection, Imaging
Drug · Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Sep 25, 2026, 12:20 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Development and Evaluation of Magnetic Resonance Imaging Acquisition and Analysis Methods

NCT02091518
View directory record Official record
Conditions
Healthy
Interventions
MR Screening Questionnaire, Magnetic Resonance Imaging Acquisition and Analysis
Behavioral · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
672 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 25, 2026, 12:20 AM EDT
Recruiting No phase listed Observational

Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)

NCT03067467
View directory record Official record
Conditions
Brain Tumor Adult
Interventions
Hyperpolarized 13C-Pyruvate, Gadolinium
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 25, 2026, 12:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Contrast- Enhanced Whole-Heart Coronary MRA at 3.0T (Tesla)

NCT02092428
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Image Quality, Diagnostic Accuracy
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Sep 25, 2026, 12:20 AM EDT
Withdrawn Phase 3 Interventional

68Ga Citrate PET/MRI for Evaluation of Fever of Unknown Origin (FUO)

NCT04139395
View directory record Official record
Conditions
Fever of Unknown Origin
Interventions
68Ga-Citrate PET/MRI, 67Ga-Citrate SPECT, Positron Emission Tomography, Magnetic Resonance Imaging, SPECT
Drug · Device
Lead sponsor
Carina Mari Aparici
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2022 · Synced Sep 25, 2026, 12:20 AM EDT
Recruiting Phase 4 Interventional

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

NCT04373564
View directory record Official record
Conditions
Motor Function, Cognitive Function, Contrast Media
Interventions
Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain, Gadolinium Measurements, Gadoxetate disodium, Gadobenate dimeglumine, Gadodiamide, Gadoterate meglumine, Gadobutrol, Gadoteridol
Procedure · Drug
Lead sponsor
Guerbet
Industry
Eligibility
18 Years to 64 Years
Enrollment
2,076 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
16
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 25, 2026, 12:20 AM EDT
Active, not recruiting Phase 2 Interventional

Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme

NCT02177578
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Temozolomide, Subventricular Zone radiation, Neural Progenitor Cell Sparing radiation
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 25, 2026, 12:20 AM EDT
Completed Early Phase 1 Interventional

Novel Imaging Markers in SPMS

NCT05357833
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis
Interventions
Ferumoxytol infusion, Gadoteridol, MRI Brain and Cervical Spine
Drug · Diagnostic Test
Lead sponsor
University of Utah
Other
Eligibility
35 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 25, 2026, 12:20 AM EDT
Not yet recruiting Not applicable Interventional

Hypoxia-targeted Radiotherapy Boost for GBM

NCT07769918
View directory record Official record
Conditions
Glioblastoma (GBM)
Interventions
Dynamic susceptibility contrast MRI (DSC-MRI), Cercare Medical Neurosuite (CMN) DSC-MRI-derived hypoxia maps, Varian TrueBeam
Device · Other · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 25, 2026, 12:20 AM EDT
Completed Early Phase 1 Interventional

Myocardial Perfusion Magnetic Resonance Imaging Using Regadenoson

NCT00881218
View directory record Official record
Conditions
Ischemic Heart Disease
Interventions
Regadenoson
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 9, 2012 · Synced Sep 25, 2026, 12:20 AM EDT
Completed Phase 2 Interventional Results available

Gadoxetate Enhanced Imaging Study to Detect Prostate Cancer

NCT01867424
View directory record Official record
Conditions
Prostate Cancer
Interventions
Eovist
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Sep 25, 2026, 12:20 AM EDT
Completed Not applicable Interventional Results available

Dispersal Pattern for Spine Injections (Gadolinium Contrast)

NCT02217280
View directory record Official record
Conditions
Cervical Radiculopathy
Interventions
Injection with Gadolinium
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Sep 25, 2026, 12:20 AM EDT
Recruiting No phase listed Observational

Registering Genomics and Imaging of Tumors (ReGIT)

NCT05386043
View directory record Official record
Conditions
Glioma
Interventions
FET F-18, O-15 Radioisotope, CT scan, MRI with gadolinium-based contrast, Biopsy Collection
Drug · Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 25, 2026, 12:20 AM EDT
Active, not recruiting Not applicable Interventional

Evaluation of Gadolinium Based Contrast Agents for Portable MR Imaging Systems

NCT07296263
View directory record Official record
Conditions
Intra-axial Tumors, Extra-axial Tumors, Infection/Inflammatory Lesions
Interventions
Portable MRI (pMRI), Gadolinium-Based Contrast Agent (GBCA)
Device · Drug
Lead sponsor
Hyperfine
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
6
States / cities
Altamonte Springs, Florida • Boston, Massachusetts • Amherst, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 25, 2026, 12:20 AM EDT
Completed Not applicable Interventional Results available

Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases

NCT00103038
View directory record Official record
Conditions
Central Nervous System Lymphoma, Malignant Glioma, Metastatic Malignant Neoplasm in the Brain
Interventions
3 Tesla Magnetic Resonance Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Ferumoxytol, Gadolinium, MRI-Based Angiogram
Procedure · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Sep 25, 2026, 12:20 AM EDT
Completed Not applicable Interventional Results available

Advanced MRI Scan Before and After Radiation Therapy for the Detection of Intracranial Metastasis

NCT04870645
View directory record Official record
Conditions
Malignant Solid Neoplasm
Interventions
Advanced Magnetic Resonance Imaging, Conventional Magnetic Resonance Imaging, Gadolinium-Chelate, Iopamidol
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Sep 25, 2026, 12:20 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Coronary Atherosclerosis T1-Weighted Characterization (CATCH)

NCT03504956
View directory record Official record
Conditions
Coronary Atherosclerosis
Interventions
Cardiac MRI, Contrast, Beta blocker
Device · Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 25, 2026, 12:20 AM EDT
Completed Not applicable Interventional Results available

Artifact-Free High-Resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies

NCT01949844
View directory record Official record
Conditions
Coronary Artery Disease, CAD
Interventions
regadenoson, Optimark®, Myocardial perfusion MRI
Drug · Device
Lead sponsor
Daniel S. Berman
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2018 · Synced Sep 25, 2026, 12:20 AM EDT
Completed Phase 2 Interventional Results available

Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions

NCT04307186
View directory record Official record
Conditions
Central Nervous System Pathology
Interventions
Gadoquatrane (BAY1747846), Gadobutrol (Gadovist/Gadavist)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Chicago, Illinois • Iowa City, Iowa • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Sep 25, 2026, 12:20 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Gadopiclenol vs Gadoxetate MRI for Liver Lesions

NCT06596616
View directory record Official record
Conditions
Liver Lesion
Interventions
Radiology, Gadopiclenol
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 89 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 25, 2026, 12:20 AM EDT